tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jorgensen WL Rusting of the lock and key model for protein-ligand binding. 1991 Science pmid:1719636
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Strasser S et al. The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. 1991 Transplant. Proc. pmid:1703709
Cryan J et al. FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. 1991 Biochem. Biophys. Res. Commun. pmid:1719972
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Karlsson H et al. The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. 1991 Immunol. Lett. pmid:1720417
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. 1991 Nephrol News Issues pmid:1720511
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
The discovery of FK-506 and U.S. development. 1991 Nephrol News Issues pmid:1720512
Zheng B et al. Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. 1991 Transplant. Proc. pmid:1703717
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
Sumpio BE and Phan S Nephrotoxic potential of FK 506. 1991 Transplant. Proc. pmid:1721278
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
McCarthy SA et al. Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. 1991 Transplant. Proc. pmid:1721314
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Jain AB et al. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. 1991 Transplant. Proc. pmid:1721347
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
de Paulis A et al. Characterization of the anti-inflammatory effect of FK-506 on human mast cells. 1991 J. Immunol. pmid:1721644
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Lagodziński Z et al. Effect of FK 506 on B-cell responses. 1991 Transplant. Proc. pmid:1703359
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Pirsch JD et al. Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 1991 Transplant. Proc. pmid:1721406
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Steinmann B et al. Mechanism of action of FK 506 and cyclosporin. 1991 Lancet pmid:1704088
Sewing KF and Christians U FK 506. 1991 Lancet pmid:1704090
Wiederrecht G et al. FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1704127
Ito T et al. Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. 1991 Transplant. Proc. pmid:1721437
DeValeria PA et al. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. 1991 Transplant. Proc. pmid:1721438
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Albers MW et al. Relationship of FKBP to PKCI-2. 1991 Nature pmid:1710782
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Neuberger J FK 506--a promise of good things to come? 1991 Hepatology pmid:1711005
Halloran PF and Madrenas J The mechanism of action of cyclosporine: a perspective for the 90's. 1991 Clin. Biochem. pmid:1711939
Palaszynski EW et al. Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. 1991 Clin. Biochem. pmid:1711940
Shiraki K et al. Effect of FK-506 on replication of human cytomegalovirus in vitro. 1991 J. Antibiot. pmid:1712008
Lhoëst G et al. Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. 1991 Pharm Acta Helv pmid:1722046
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Starzl TE et al. [Clinical experience with FK 506]. 1991 Presse Med pmid:1722311
Granelli-Piperno A and McHugh P Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1722332
Nelson PA et al. cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. 1991 Gene pmid:1722474
Chen MF et al. The influence of FK-506 on the thymus and spleen in normal C3H/He mice: flow cytometric analysis of lymphocyte subpopulations. 1991 Immunol. Lett. pmid:1722778
Sakai K et al. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. 1991 Brain Res. pmid:1723023
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Forrest MJ et al. FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. 1991 Biochem. Pharmacol. pmid:1716098
Weaver JL et al. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. 1991 Immunopharmacol Immunotoxicol pmid:1723084
Lautenschlager I et al. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. 1991 Transplant. Proc. pmid:1714650
DiLella AG and Craig RJ Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. 1991 Biochemistry pmid:1716149
Epand RF and Epand RM The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. 1991 Anticancer Drug Des. pmid:1714737
Christians U et al. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. 1991 Clin. Biochem. pmid:1714802
Turka LA and Thompson CB Structure-function relationship of immunosuppressive drugs: a cautionary tale. 1991 Hepatology pmid:1714876
Brizuela L et al. Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. 1991 Mol. Cell. Biol. pmid:1715022
Heitman J et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 1991 Science pmid:1715094
Morris RE Rapamycin: FK506's fraternal twin or distant cousin? 1991 Immunol. Today pmid:1715165